Stockreport

First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinami [Read more]